Systemic energy homeostasis in Huntington's disease patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 11, 2010, Pages 1233-1237

  Aziz, N Ahmad ^a   Pijl, Hanno ^a   Frölich, Marijke ^a   Snel, Marieke ^a   Streefland, Trea C M ^a   Roelfsema, Ferdinand ^a   Roos, Raymund A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; GLYCEROL;

ADULT; ARTICLE; BODY MASS; CAG REPEAT; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENERGY EXPENDITURE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOTOR DYSFUNCTION; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; CALORIMETRY, INDIRECT; ENERGY METABOLISM; FEMALE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HOMEOSTASIS; HUMANS; HUNTINGTON DISEASE; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRINUCLEOTIDE REPEATS;

EID: 78649579040     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.191833     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
2. Bates G, Harper PS, Jones L. Huntington's disease. 3rd edn. New York: Oxford University Press, 2002.
3. Aziz NA, Swaab DF, Pijl H, et al. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007;18:223-51.
4. Aziz NA, van der Burg JM, Landwehrmeyer GB, et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008;71:1506-13.
5. Trejo A, Tarrats RM, Alonso ME, et al. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004;20:192-6.
6. Bjorkqvist M, Fex M, Renstrom E, et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 2005;14:565-74. (Pubitemid 40309582)
7. Martin B, Golden E, Carlson OD, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies and extends survival in a mouse model of Huntington's disease. Diabetes 2008;58:318-28.
8. Smith R, Bacos K, Fedele V, et al. Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion. Hum Mol Genet 2009;18:3942-54.
9. van der Burg JM, Bacos K, Wood NI, et al. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008;29:41-51.
10. Lalic NM, Maric J, Svetel M, et al. Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 2008;65:476-80.
11. Underwood BR, Broadhurst D, Dunn WB, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006;129:877-86.
12. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004;3:169-78. (Pubitemid 38229951)
13. van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009;8:765-74.
14. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006;24:961-7.
15. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127:59-69.
16. St Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006;127:397-408. (Pubitemid 44572377)
17. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006;4:349-62.
18. Greenamyre JT. Huntington's disease - making connections. N Engl J Med 2007;356:518-20.
19. Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC-1{alpha} function in muscle in Huntington's disease. Hum Mol Genet 2009;18:3048-65.
20. Phan J, Hickey MA, Zhang P, et al. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet 2009;18:1006-16.
21. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90. (Pubitemid 36223280)
22. Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-42.
23. Jazet IM, Pijl H, Frolich M, et al. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism 2005;54:705-12.
24. Simonson DC, DeFronzo RA. Indirect calorimetry: methodological and interpretative problems. Am J Physiol 1990;258:E399-412.
25. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959;82:420-30.
26. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulindependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38:387-95.
27. Gaba AM, Zhang K, Marder K, et al. Energy balance in early-stage Huntington disease. Am J Clin Nutr 2005;81:1335-41.
28. Goodman AO, Murgatroyd PR, Medina-Gomez G, et al. The metabolic profile of early Huntington's diseaseda combined human and transgenic mouse study. Exp Neurol 2008;210:691-8.
29. Pratley RE, Salbe AD, Ravussin E, et al. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000;47:64-70.
30. Bergman BC, Cornier MA, Horton TJ, et al. Effects of fasting on insulin action and glucose kinetics in lean and obese men and women. Am J Physiol Endocrinol Metab 2007;293:E1103-11.
31. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens 2001;19:523-8.
32. Young JB, Landsberg L. Impaired suppression of sympathetic activity during fasting in the gold thioglucose-treated mouse. J Clin Invest 1980;65:1086-94. (Pubitemid 10043604)
33. Kobal J, Meglic B, Mesec A, et al. Early sympathetic hyperactivity in Huntington's disease. Eur J Neurol 2004;11:842-8. (Pubitemid 39665063)
34. Fain JN, Del Mar NA, Meade CA, et al. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum Mol Genet 2001;10:145-52.
35. Boesgaard TW, Nielsen TT, Josefsen K, et al. Huntington's disease does not appear to increase the risk of diabetes mellitus. J Neuroendocrinol 2009;21:770-6.
36. Hurlbert MS, Zhou W, Wasmeier C, et al. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999;48:649-51.
37. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
38. Benn CL, Sun T, Sadri-Vakili G, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008;28:10720-33.
39. Seong IS, Ivanova E, Lee JM, et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005;14:2871-80.
40. Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002;19:724-9.